Skip to main content
SpringerLink
Log in

PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events Frontiers in Oncology : 29 Sep 2023. Available from: URL: https://doi.org/10.3389/fonc.2023.1191681

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy. Reactions Weekly 1980, 10 (2023). https://doi.org/10.1007/s40278-023-48202-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-48202-7

Search

Navigation